Concepedia

Christopher P. Fox

CP

94

Publications

6.2K

Citations

41

H-Index

2004

Active since

Affiliations

Nottingham University Hospitals NHS Trust(Current)

University College London

Oxford University Hospitals NHS Trust

The Christie NHS Foundation Trust

University of Nottingham

Christopher P. Fox is an author at Nottingham University Hospitals NHS Trust specializing in medicine, oncology, and immunotherapy.

ORCID

Top concepts

Publications per year

2004–2025

94

Publications

94

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 582 citations · Full text

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 364 citations · Full text

, , +12

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Peter Hillmen, Andy C. Rawstron, Kristian Brock et al. · Journal of Clinical Oncology · 2019 · 264 citations · Full text

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma

Caroline Wilson, Diana Jurk, Nicola Fullard et al. · Nature Communications · 2015 · 175 citations · Full text

Rows per page

1–5 of 94